Background: The incidence of Oesophageal Adenocarcinoma (OAC) has risen 6-fold in the western world in the last forty years but survival is poor. Increased molecular understanding of this heterogeneous disease is needed to improve treatment selection and develop novel therapies. This study uses gene expression data to perform unbiased molecular subtyping and identify prognostic subgroups in OAC. Methods: Transcriptional profiling of 274 treatment naïve OAC biopsies was performed using the Almac Diagnostics Xcel array TM . All patients received platinum-based neo-adjuvant chemotherapy prior to surgical resection at four United Kingdom centres between 2004-2012. Iterative semi-supervised clustering based on gene expression level variability was performed followed by functional enrichment using DAVID. Cluster membership was assessed for independence of known prognostic factors using Cox proportional hazards regression for relapse-free (RFS) and overall survival (OS). Clustering was repeated with a published 51-gene hypoxia signature with validation in the TGCA OAC (n ¼ 65) and oesophageal squamous cell carcinoma (n ¼ 45) cohorts. Results: Patients were clustered into two groups with significantly different RFS (HR ¼ 0.54, p ¼ 0.05) and OS (HR ¼ 0.52, p ¼ 0.04). There were no significant differences in known prognostic factors such as pathological response, lymphovascular invasion and resection margin. Pathway analysis revealed the PI3K-AKT, p53, Tumour Necrosis Factor and Hypoxia Inducible Factor 1 (HIF-1) signalling pathway to be upregulated in the poor prognostic group. To further investigate the role of the HIF-1 pathway, a hypoxia 51-gene signature was applied. Patients were stratified into hypoxia low and high groups with improved RFS (HR 0.64, 95% CI 0.42-0.97; p ¼ 0.04) and OS (HR 0.67, 95% CI 0.44-1.02; p ¼ 0.06) in the hypoxia-low group. Increased OS for the hypoxia-low group was also observed in the TCGA cohort (HR 0.49, 95% CI 0.24-0.97; p ¼ 0.04). There was a significant association between membership of the poor prognostic and hypoxia-low cluster groups (p < 0.001). Conclusions: Molecular stratification and application of a hypoxia gene signature identifies a poor prognostic group of OAC patients characterised by upregulation of hypoxia signalling. Legal entity responsible for the study: Queen's University Belfast.
Background: Multimodality treatments of patients with esophageal adenocarcinoma (EAC) improve survival, but the optimal treatment strategy remains undetermined. This study aimed to compare response, local recurrence and survival outcomes in patients undergoing neoadjuvant paclitaxel and carboplatin chemoradiotherapy with 41Gy (CROSS) with neoadjuvant cisplatin and 5-fluoruracil (CF)-based chemoradiotherapy with 45Gy (CFRT) or CF chemotherapy followed by oesophagectomy for EAC. Methods: Patients who underwent CROSS, CFRT or CF followed by surgery for EAC were identified from two single institution prospective databases from Australia and the Netherlands (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) and included in this study. After pair-wise propensity score matching (caliper 0.2) using pre-treatment variables (age, gender, year of treatment, tumor length and site, and clinical T stage), we compared the impact of the treatments on pathological outcomes, patterns of recurrence and overall survival. Results: Of the 637 eligible patients, 429 patients were analysed following propensity score matching. This resulted in 143 patients in each group with median follow up 61 months. CROSS and CFRT demonstrated significantly higher pathological complete response rates (p < 0.001), lower ypT stage (p < 0.001) and lower ypN stage (p < 0.001) compared with CF. There were no statistically significant differences in 5year local recurrence-free survival between the three treatment groups: CROSS 76% (95%CI: 68-85); CFRT 71% (95%CI: 64-81); and CF 66% (95%CI: 65-76). Similarly, there were no significant differences in 5-year overall survival rates between groups: CROSS 52% (95%CI: 44-62); CFRT 40% (95%CI: 32-49); and 46% (95%CI: 38-55 Background: The concurrent chemoradiotherapy followed by surgery is the standard treatment for locally advanced esophageal cancer (LAEC) and the role of induction chemotherapy (IC) remains unclear. We aimed to study if the addition of IC to standard treatment increases the rate of pathologic complete response (pCR). 
